Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX16
|
| gptkbp:brand |
gptkb:Rozlytrek
|
| gptkbp:CASNumber |
1108743-60-7
|
| gptkbp:developer |
gptkb:Roche
gptkb:Ignyta |
| gptkbp:eliminationHalfLife |
20 hours
|
| gptkbp:hasMolecularFormula |
C31H34F2N6O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Entrectinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits TRK, ROS1, and ALK kinases
|
| gptkbp:metabolism |
gptkb:CYP3A4
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
77%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea edema constipation dizziness fatigue weight gain dysgeusia |
| gptkbp:target |
gptkb:ALK
gptkb:TRK_A gptkb:TRK_B gptkb:TRK_C ROS1 |
| gptkbp:usedFor |
treatment of non-small cell lung cancer
treatment of solid tumors with NTRK gene fusion |
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|